دورية أكاديمية
أعرض في EDS

Declining Prevalence of Human Immunodeficiency Virus (HIV)-Associated Neurocognitive Disorders in Recent Years and Associated Factors in a Large Cohort of Antiretroviral Therapy-Treated Individuals With HIV.

التفاصيل البيبلوغرافية
العنوان: Declining Prevalence of Human Immunodeficiency Virus (HIV)-Associated Neurocognitive Disorders in Recent Years and Associated Factors in a Large Cohort of Antiretroviral Therapy-Treated Individuals With HIV.
المؤلفون: Mastrorosa I; Clinical Department of Infectious Diseases and Research, HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy., Pinnetti C; Clinical Department of Infectious Diseases and Research, HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy., Brita AC; Clinical Department of Infectious Diseases and Research, Psychology Service, National Institute for Infectious Diseases Lazzaro Spallanzani Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy., Mondi A; Clinical Department of Infectious Diseases and Research, HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy., Lorenzini P; Clinical Department of Infectious Diseases and Research, HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.; National Center for Disease Prevention and Health Promotion, National Institute of Health, Rome, Italy., Del Duca G; Clinical Department of Infectious Diseases and Research, HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy., Vergori A; Clinical Department of Infectious Diseases and Research, HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy., Mazzotta V; Clinical Department of Infectious Diseases and Research, HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy., Gagliardini R; Clinical Department of Infectious Diseases and Research, HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy., Camici M; Clinical Department of Infectious Diseases and Research, HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy., De Zottis F; Clinical Department of Infectious Diseases and Research, HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy., Fusto M; Clinical Department of Infectious Diseases and Research, HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy., Plazzi MM; Clinical Department of Infectious Diseases and Research, HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy., Grilli E; Clinical Department of Infectious Diseases and Research, HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy., Bellagamba R; Clinical Department of Infectious Diseases and Research, HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy., Cicalini S; Clinical Department of Infectious Diseases and Research, HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy., Antinori A; Clinical Department of Infectious Diseases and Research, HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.
المصدر: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2023 Feb 08; Vol. 76 (3), pp. e629-e637.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE
أسماء مطبوعة: Publication: Jan. 2011- : Oxford : Oxford University Press
Original Publication: Chicago, IL : The University of Chicago Press, c1992-
مواضيع طبية MeSH: HIV* , HIV Infections*/complications , HIV Infections*/drug therapy , HIV Infections*/epidemiology, Humans ; Prevalence ; Cross-Sectional Studies ; Neurocognitive Disorders/epidemiology
مستخلص: Background: HIV-associated neurocognitive disorders (HAND) have been suggested as persistent even with effective antiretroviral therapy (ART). Aims were to evaluate HAND prevalence and associated factors, in a large cohort of people-with-HIV (PWH).
Methods: ART-treated PWH, underwent a neuropsychological examination through a battery of 12 tests exploring 5 different domains, between 2009 and 2020, were included in this cross-sectional analysis. HAND were classified according to Frascati's criteria. Participants were defined as complaining or not-complaining if a cognitive complaint was reported or not. Chi-square for trend and multivariable logistic regression were fitted.
Results: Overall, 1424 PWH were enrolled during four three-years periods. HAND prevalence was 24%; among complainers (572/1424), it was 38%, higher than among not-complainers (15%). Over the study period, a decreasing HAND prevalence was found in the entire population (P < 0.001) and in complaining (P < 0.001); in not-complaining it remained stable (P = 0.182). Factors associated with HAND were older age, lower educational level, lower current CD4+ T-cell count and HCV co-infection. Compared to nonnucleoside reverse transcriptase inhibitors, receiving dual and integrase strand transfer inhibitor (INSTI)-based therapies was associated with a decreased risk of HAND, as well as being tested in more recent years.
Conclusions: In this large cohort of ART-treated PWH, mostly virologically suppressed, a remarkable decreasing HAND prevalence was observed. Besides HIV- and patient-related factors, the reduced risk of HAND found with dual and INSTI-based regimens along with a more recent ART initiation, could suggest a potential role of new treatment strategies in this decline, due to their greater virologic efficacy and better tolerability.
Competing Interests: Potential conflicts of interest. Andrea Antinori has served as a paid consultant to and received payment or honoraria from Astra-Zeneca, Gilead Sciences, GlaxoSmithKline, Janssen-Cilag, Merck Sharp and Dohme, Roche, Theratotecnologies, ViiV Healthcare. Rita Bellagamba reports payment or honoraria from Merck Sharp and Dohme, and participation on a Data Safety Monitoring Board or Advisory Board from ViiV Healthcare, Gilead Sciences, and Merck Sharp and Dohme. Marta Camici received institutional grant and support for attending meetings and/or travel from Gilead Sciences. Stefania Cicalini reports consulting fees paid to self from ViiV Healthcare, Jansen-Cilag, Merck Sharp and Dohme, Gilead Sciences; payment or honoraria from ViiV Healthcare, Jansen-Cilag, Merck Sharp and Dohme, and Gilead Sciences. Roberta Gagliardini reports payments to their institution from Gilead Sciences, speakers' honoraria/educational activities for ViiV Healthcare, Merck Sharp and Dohme and Gilead Sciences, support for attending meetings and/or travel from ViiV Healthcare, advisor for Theratechnologies, Janssen-Cilag and Gilead Sciences. Ilaria Mastrorosa received institutional grant and support for attending meetings and/or travel from Gilead Sciences. Carmela Pinnetti received personal fee from Gilead Sciences for a case presentation and a travel grant and served on an advisory board for Janssen-Cilag. Alessandra Vergori received institutional grant from Gilead Sciences, speakers' honoraria/educational activities for Merck Sharp and Dohme and Janssen-Cilag, advisor for Janssen-Cilag. The other co-authors declare no conflicts of interests.
(© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
References: Infection. 2020 Feb;48(1):37-42. (PMID: 31691905)
Neurology. 2015 Jan 20;84(3):231-40. (PMID: 25540304)
J Neurovirol. 2018 Apr;24(2):141-145. (PMID: 28752495)
BMC Infect Dis. 2011 Dec 28;11:356. (PMID: 22204557)
AIDS. 2010 Jun 1;24(9):1243-50. (PMID: 19996937)
Sci Rep. 2021 May 28;11(1):11289. (PMID: 34050221)
AIDS. 2007 Sep 12;21(14):1915-21. (PMID: 17721099)
Neurology. 2009 Jul 28;73(4):309-14. (PMID: 19636051)
Clin Infect Dis. 2015 Feb 1;60(3):473-80. (PMID: 25362201)
Neurology. 2010 Dec 7;75(23):2087-96. (PMID: 21135382)
Neurology. 2010 Apr 20;74(16):1260-6. (PMID: 20237308)
Clin Infect Dis. 2022 Apr 28;74(8):1323-1328. (PMID: 34329400)
J Acquir Immune Defic Syndr. 2021 Aug 15;87(5):1196-1204. (PMID: 33901102)
AIDS. 2007 May 31;21(9):1109-17. (PMID: 17502721)
J Neuroimmune Pharmacol. 2013 Dec;8(5):1114-22. (PMID: 24114509)
J Neurovirol. 2005 Jul;11(3):265-73. (PMID: 16036806)
Neurology. 2012 Feb 14;78(7):485-92. (PMID: 22330412)
J Neurovirol. 2018 Jun;24(3):339-349. (PMID: 29516346)
J Acquir Immune Defic Syndr. 2014 Oct 1;67(2):120-7. (PMID: 24991974)
J Neurovirol. 2011 Feb;17(1):3-16. (PMID: 21174240)
Neurology. 2016 Jan 26;86(4):334-40. (PMID: 26718568)
PLoS One. 2013 Apr 30;8(4):e61949. (PMID: 23646111)
Neurology. 2007 Oct 30;69(18):1789-99. (PMID: 17914061)
Infection. 2013 Dec;41(6):1103-9. (PMID: 23839213)
AIDS. 2011 Sep 10;25(14):1747-51. (PMID: 21750419)
Lancet Neurol. 2014 Nov;13(11):1139-1151. (PMID: 25316020)
Clin Infect Dis. 2021 Sep 15;73(6):1113-1118. (PMID: 33904889)
AIDS Behav. 2018 May;22(5):1573-1583. (PMID: 28144792)
Clin Infect Dis. 2020 Jun 10;70(12):2641-2648. (PMID: 31755936)
AIDS. 2021 Dec 1;35(15):2469-2480. (PMID: 34411034)
Ann Neurol. 2008 Feb;63(2):213-21. (PMID: 17894380)
Lancet HIV. 2020 Jul;7(7):e504-e513. (PMID: 32621876)
Neurology. 2013 Jan 22;80(4):371-9. (PMID: 23303852)
Neurology. 2015 Jan 20;84(3):241-50. (PMID: 25503616)
Curr Top Behav Neurosci. 2021;50:301-327. (PMID: 31907879)
HIV Clin Trials. 2011 Nov-Dec;12(6):333-8. (PMID: 22189152)
AIDS. 2019 Jul 15;33(9):1477-1483. (PMID: 31008801)
Neurology. 2020 Nov 10;95(19):e2610-e2621. (PMID: 32887786)
Neurology. 2014 Jun 10;82(23):2055-62. (PMID: 24814848)
Ann Neurol. 2004 Sep;56(3):416-23. (PMID: 15349869)
HIV Med. 2020 Jan;21(1):30-42. (PMID: 31589807)
فهرسة مساهمة: Keywords: AIDS; HIV; HIV-associated neurocognitive disorders (HAND); integrase strand transfer inhibitor; neurocognitive impairment
تواريخ الأحداث: Date Created: 20220819 Date Completed: 20230210 Latest Revision: 20230220
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9907497
DOI: 10.1093/cid/ciac658
PMID: 35982541
قاعدة البيانات: MEDLINE
الوصف
تدمد:1537-6591
DOI:10.1093/cid/ciac658